JUN 08, 2021 7:30 AM PDT

Is the Pfizer-BioNtech Vaccine Variant-Resistant?

WRITTEN BY: Tara Fernandez

Genetic variants of SARS-CoV-2 have emerged over the course of the pandemic, threatening public health efforts to limit COVID-19 transmissions. Variants of concern are particularly worrying—these may be more transmissible, cause more severe disease symptoms, or evade currently available diagnostics, treatments, or vaccines.

Recently, researchers studying immune responses in people who received the Pfizer-BioNTech COVID vaccine observed that these individuals have much lower levels of antibodies against the Delta variant of SARS-CoV-2, as compared to other variants in circulation.

The Delta variant, first detected in India, has rapidly become the most dominant variant in the UK, and the efficacy of current COVID-19 vaccines to protect against this variant is still unknown. A series of 12 mutations in the spike protein differentiates the Delta variant from the virus first detected in Wuhan in late 2019.

This study by scientists at the Francis Crick Institute, the largest of its kind, sought to bridge this gap, investigating how vaccine-induced antibodies could neutralize emerging variants of concern in healthy adults. They tested the efficacy of neutralizing antibodies against five SARS-CoV-2 variants: the original strain, the D614G strain that was dominant in the European first wave in April 2020, and the Alpha, Beta, and Delta variants.

In individuals who had received both doses of the Pfizer-BioNTech vaccine, neutralizing antibody levels were five times lower against the Delta variant compared to those against the original strain (or the “blueprint” for current vaccines). These protective antibody responses were found to be even lower for those who had only received one dose of the vaccine.

"This virus will likely be around for some time to come, so we need to remain agile and vigilant,” said infectious disease specialist, Emma Wall. “Our study is designed to be responsive to shifts in the pandemic so that we can quickly provide evidence on changing risk and protection.”

"The most important thing is to ensure that vaccine protection remains high enough to keep as many people out of hospital as possible. And our results suggest that the best way to do this is to quickly deliver second doses and provide boosters to those whose immunity may not be high enough against these new variants," Wall added.

 

Sources: The Lancet, The Francis Crick Institute.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 21, 2021
Health & Medicine
Topical Probiotics Are a Beneficial Acne Treatment
APR 21, 2021
Topical Probiotics Are a Beneficial Acne Treatment
Research underway is showing topical probiotics to be a beneficial treatment for acne vulgaris. Topical probiotics are a ...
APR 27, 2021
Immunology
Breakthrough Malaria Vaccine Is a Ray of Hope
APR 27, 2021
Breakthrough Malaria Vaccine Is a Ray of Hope
University of Oxford scientists have developed a vaccine against malaria, which they describe as having “unprecede ...
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 28, 2021
Microbiology
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
JUN 28, 2021
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
According to WHO there have been six cholera pandemics since the pathogen emerged from the Ganges river delta sometime i ...
JUL 20, 2021
Coronavirus
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
JUL 20, 2021
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
New research found that both pregnant and lactating people who receive the COVID-19 vaccine can pass antibodies to their ...
Loading Comments...